Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA extends physician prescribing authority

Executive Summary

Drug Enforcement Agency issues a proposed rule to allow physicians to prescribe multiple prescriptions of Schedule II controlled substances in a single visit, for up to a 90-day supply; doctors were previously restricted from issuing refills for Schedule II prescriptions. DEA's proposed rule was prompted by complaints from healthcare professionals about the existing policy; a 60-day public comment period began Sept. 6 following publication of the proposed rule. A policy statement accompanying the proposed rule, "Dispensing Controlled Substances for the Treatment of Pain," provides information requested by physicians on DEA's position regarding the issue. DEA also launches new page on their website, "Cases Against Doctors," to highlight criminal acts committed by physicians who are subject to prosecution or administrative action...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel